Navigation Links
Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth
Date:4/20/2009

ysine-specific demethylase 1 (LSD1), induce re-expression of epigenetically silenced genes, and inhibit the growth of established human tumors in vivo

Presentation Start/End Time: Tuesday, Apr 21, 2009, 8:00 AM -12:00 PM

Location: Hall B-F, Poster Section 15

Abstract Number: LB-205

Presentation Title: PG11047, A Polyamine Analog, Induces Potent Antitumor Activity in a Preclinical Model of Non-Small Cell Lung Cancer in Combination with Cisplatin.

Presentation Start/End Time: Tuesday, Apr 21, 2009, 8:00 AM -12:00 PM

Location: Hall B-F, Poster Section 26

Abstract Number: 3194

Presentation Title: Pediatric Preclinical Testing Program (PPTP) evaluation of the novel polyamine analogue PG11047

Presentation Start/End Time: Tuesday, Apr 21, 2009, 8:00 AM -12:00 PM

Location: Hall B-F, Poster Section 10

Full abstract details are available on the ASX announcement on Progen's website: www.progen-pharma.com


'/>"/>
SOURCE Progen Pharmaceuticals Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. ProGenTech Targets Clinical Diagnostics and Applied Sciences Markets with Human Genetic Signatures Deal
2. ProGenTech Limited Appoints Executive Management Team
3. ProGenTech Completes $21 Million Series C Financing
4. Radioactive progenies of thoron can be measured accurately, thanks to the PTB
5. Neural progenitor cells as reservoirs for HIV in the brain
6. Progen Investor Teleconference Dial In Details
7. Elusive pancreatic progenitor cells found in mice
8. Imaging neural progenitor cells in the living human brain
9. Progen Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
10. Progen to Present Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Yashoda Cancer Institute Treats First Patient in India Using RapidArc Radiotherapy Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... San Rafael, CA (PRWEB) May 05, 2015 ... Snader in 2012, with the belief that ultimate Frisbee™ ... can be the next sport that engages the world. ... the youth level, by creating opportunities for young athletes ... makes this collaboration with MLU the perfect fit. , ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 NovaSom, Inc., ... upcoming episode of Innovations with Ed Begley Jr., airing ... times TBA. , This segment will focus on NovaSom, ... Viewers will learn about their AccuSom® home sleep test, ... that provides continuous patient support and next-day test results ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Every year, news ... seasons. Turns out, the worst dry eye season is spring, ... spikes in most of the United States. The only season ... water advocate Sharon Kleyne, host of the Sharon Kleyne Hour™ ... on her radio show of May 11, 2015. Kleyne is ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 McMunn ... and end-to-end automation solutions, announced today that it has ... and corporate identity. According to president and founder, Larry ... aligned with the company’s strategy for growth and expansion ... successful for the past 30 years by building close, ...
(Date:5/5/2015)... BioFit Engineered Products , a globally ... from its two latest lines at NeoCon 2015, June ... Headlining the company’s exhibit will be new Pro and ... well as the unveiling of the fifth model of ... Metzger will deliver in-booth presentations each day of the ...
Breaking Medicine News(10 mins):Health News:US Sports Camps, Nike Ultimate Camps, and Major League Ultimate Host Youth Ultimate Summer Camps in Philidelphia 2Health News:Innovations with Ed Begley, Jr. to Explore NovaSom, Inc., in Upcoming Episode 2Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 2Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 3Health News:McMunn Associates Launches New Corporate Branding with New Website 2Health News:BioFit to Introduce New Models from Latest Specialized Ergonomic Seating Lines at NeoCon 2015 2Health News:BioFit to Introduce New Models from Latest Specialized Ergonomic Seating Lines at NeoCon 2015 3
... D. Eilers Professor of Medicine and Health Care Management and ... the Wharton School, was presented with the Alpha Omega Alpha ... of Medical Colleges (AAMC). The award was presented on ... Recognizing Dr. Asch, the AAMC said, "Dr. ...
... don,t help those with existing disease , TUESDAY, Nov. ... from a young age might prevent early signs of ... study in mice. , Recent research suggests that the ... in the development of Alzheimer,s. In the new study, ...
... ... Dr Cheryl Effron of Cosmetic Dermatology of Orange County offers Sculptra Aesthetic@ at affordable ... (PRWEB) ... of Cosmetic Dermatology of Orange County offers Sculptra Aesthetic@ at affordable prices., , , ...
... ... to have policyholders select and pay extra for either a plan which covers abortion or ... ... over abortion coverage and the possibility that the same thing could happen again in the ...
... ... a North American company, is expanding its cutting edge vibration exercise technology into South ... the Pro Elite, Air Reflex and Contour Plus, are now available in South America. ... (Vocus) November ...
... ATLANTA Emory University Rollins School of Public Health ... topics at the American Public Health Association,s annual meeting ... national recommendations that a physician screen chest pain patients ... Department (ED). Additional public health research findings from ...
Cached Medicine News:Health News:David A. Asch, M.D., M.B.A., receives AAMC Distinguished Teacher Award 2Health News:FDA-Approved Sculptra@ Now Offers by Orange County Dermatologist Dr. Cheryl Effron 2Health News:“Think Outside the Box” Blog Proposes Better Abortion Compromise for Health Reform 2Health News:WAVE's Revolutionary Whole-Body Advanced Vibration Exercise Is Now Available in South America 2Health News:Some chest pain patients wait longer than 10 minutes to see ER physician 2
(Date:5/5/2015)... Calif. , May 5, 2015  Abaxis, Inc. (NasdaqGS: ... analysis systems, announced today that Clint Severson , chairman ... America Merrill Lynch 2015 Health Care Conference on Tuesday, May ... held at the Encore at the Wynn in ... is a worldwide developer, manufacturer and marketer of portable blood ...
(Date:5/5/2015)... --  Cynosure, Inc. (Nasdaq: CYNO ), which ... and precision surgical applications worldwide, today reported financial results ... First-Quarter Highlights: , North America product revenue ... $0.15 per share; GAAP earnings break-even , Cash ... "Cynosure delivered 21 percent year-over-year top-line growth ...
(Date:5/5/2015)... , May 5, 2015  Stryker Orthopaedics announced ... Ponte Vedra, FL.  Since becoming the ... Champions Tour" over one year ago, the company has ... Tour combined, with its onsite activation the Stryker Mobility ... on the importance of joint health. Proving to be ...
Breaking Medicine Technology:Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 2Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 3Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 4Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 5Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 6Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 7Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 8Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 9Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 10Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 11Stryker Returns to TPC Sawgrass for THE PLAYERS Championship Alongside Former Tournament Winners Fred Funk and Hal Sutton 2Stryker Returns to TPC Sawgrass for THE PLAYERS Championship Alongside Former Tournament Winners Fred Funk and Hal Sutton 3
... Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ), ... vaccines against cancers and infectious diseases, announced today the ... Trial) to treat leukemia utilizing Inovio,s new ELGEN 1000 ... being run by the University of Southampton is evaluating ...
... Masimo (Nasdaq: MASI ) announced today that it ... the period ended January 1, 2011, after the market closes on ... results will begin at 1:30 p.m. PT (4:30 p.m. ET) and ... and Mark P. de Raad, Executive Vice President and Chief Financial ...
Cached Medicine Technology:University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology 2University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology 3University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology 4University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology 5University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology 6University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology 7University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology 8University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology 9University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology 10Masimo to Report Fourth Quarter and Full Year 2010 Financial Results After Market Close on February 15, 2011 2Masimo to Report Fourth Quarter and Full Year 2010 Financial Results After Market Close on February 15, 2011 3
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
Inquire...
... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
Medicine Products: